Ruxolitinib for the management of myelofibrosis: Results of an international physician survey.

ABSTRACT:

Background

Ruxolitinib is established as treatment for symptomatic myeloproliferative neoplasm (MPN)-associated myelofibrosis. The strict inclusion and exclusion criteria and dose modification rules that applied to the COMFORTI and II studies that led to the licensing of ruxolitinib are not always applicable to routine clinical practice. Thus physicians now face decisions regarding ruxolitinib use that were not addressed in these pivotal trials.

Methods

We performed an online survey of hematologists practicing in Europe, Israel, the United Kingdom and the United States. Demographic details regarding the physicians and their practice as relates to MPNs were collected. Management decisions pertaining to the use of ruxolitinib were obtained regarding 10 clinical scenarios relat

SUBMITTER: Ellis MH 

PROVIDER: S-EPMC8190959 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature